Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 7Pancreatic Neoplasms 1Liver Neoplasms 1Digestive System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Biliary Tract Carcinoma 1Biliary Tract Adenocarcinoma 1Advanced Solid Tumor 1

Interventions

spartalizumab 3Injections 3toripalimab 2camrelizumab 2anlotinib 2Therapeutics 2Cisplatin 2Capecitabine 2tislelizumab 1pembrolizumab 1fludarabine 1donafenib 1Pemetrexed 1PM 01183 1Leucovorin 1Irinotecan 1Injections, Intravenous 1Gemcitabine 1Fluorouracil 1Cyclophosphamide 1Carboplatin 15'-Nucleotidase 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Solid Tumor × donafenib × Clear all
NCT04472858 2022-11-29

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1 Unknown
30 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡